Breast-conserving surgery with resection of the nipple–areola complex for subareolar breast carcinoma
✍ Scribed by C. Tausch; T. Hintringer; F. Kugler; C. Schmidhammer; M. Bauer; M. Aufschnaiter
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 118 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.5083
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Introduction
Breast-conserving therapy for centrally located tumours has in the past been viewed with reservation, but is now an accepted treatment. There is little published evidence, however, to show that it is safe and cosmetically acceptable.
Methods
In a prospective investigation carried out between 1996 and 2002, 44 women had surgery for 45 breast carcinomas with suspected nipple involvement. The breast was conserved and the nipple–areola complex removed. Secondary mastectomy was performed in three women because the tumour was found to reach the resection margin. Forty-one women underwent further observation. The mean tumour size at the time of operation was 18 (range 4–50) mm. Six women received preoperative chemotherapy.
Results
Histologically, there were seven preinvasive and 35 invasive cancers. No local failure had occurred at a median follow-up of 51 months. Six women developed distant metastasis, of whom five died. The mean score for cosmetic results (evaluated on a scale of 1–5 where a score of 1 was excellent) was 1·5 for patients and 1·7 for physicians.
Conclusion
Breast-conserving therapy is a safe and cosmetically acceptable alternative to mastectomy for subareolar breast cancer.
📜 SIMILAR VOLUMES
## BACKGROUND. Although in recent years there has been a dramatic increase in both the incidence of ductal carcinoma in situ (DCIS) and breast-conserving therapy for patients who have this disease, the optimal treatment for these patients remains controversial. Most data regarding outcomes have co
## BACKGROUND. The use of adjuvant tamoxifen to treat postmenopausal breast carcinoma patients as an adjunct to primary surgery is well established. The current study reports the long term results for a low risk stratum in a randomized trial of adjuvant tamoxifen. The main focus of this analysis w